Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03241745 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab in Selected Uterine Cancer Patients
A Phase 2 study of Uterine Cancer and Endometrial Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 8
- Study locations
NCT03241745 is a Phase 2 study of Uterine Cancer and Endometrial Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT03241745, a Phase 2 study of Uterine Cancer and Endometrial Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03241745
The ClinicalTrials.gov registry entry for NCT03241745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03241745 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03241745 about?
NCT03241745 is a clinical study titled "A Study of Nivolumab in Selected Uterine Cancer Patients". The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
What is the current status of trial NCT03241745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2017-08-03. Estimated completion is 2024-04-01.
What conditions does trial NCT03241745 study?
This clinical trial studies the following conditions: Uterine Cancer, Endometrial Carcinoma, Leiomyosarcoma, Clear Cell Carcinoma, Undifferentiated Sarcoma.
What interventions are being tested in trial NCT03241745?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03241745?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03241745 being conducted?
This trial has 8 study locations across New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
[18F]FES PET/.CT in Uterine Cancer
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Image-Guided Gynecologic Brachytherapy
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.